Want to see AORT full AI Analyst Report?
AORT Stock Chart & Stats
$26.38
$0.82(3.24%)
At close: 4:00 PM EDT
$26.38
$0.82(3.24%)
Day’s Range― - ―
52-Week Range$19.16 - $48.25
Previous Close$26.62
Volume427.60K
Average Volume (3M)592.24K
Market Cap
$1.13B
Enterprise Value$1.42B
Total Cash (Recent Filing)$77.32M
Total Debt (Recent Filing)$407.97M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Oct 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend Yield1.15%
Share Statistics
EPS (TTM)-0.06
Shares Outstanding48,756,220
10 Day Avg. Volume492,977
30 Day Avg. Volume592,243
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.61
Price to Sales (P/S)4.69
P/FCF Ratio-2.27K
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue3.01
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda27.84
Forecast
1Y Price Target
$40.31Price Target Upside52.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$490.64M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginsArtivion has demonstrated durable top-line expansion while preserving strong gross economics. Revenue growth provides room to scale the commercial platform, and stable gross margins suggest its products retain meaningful value in a specialized medical-device market.
Product Growth And Market GainsGrowth across important product platforms, including share gains for On-X, indicates improving commercial traction rather than reliance on a single temporary boost. Expanding adoption can strengthen physician familiarity, support repeat hospital purchasing, and reinforce Artivion’s position in cardiovascular procedures.
Expanded Aortic PortfolioThe Endospan acquisition broadens Artivion’s aortic offering and creates a platform for additional PMA programs. A more complete portfolio can improve the company’s ability to serve complex procedures, deepen surgeon relationships, and provide a multi-year pathway for product-led growth.
Bears Say
Inconsistent Profitability And Cash FlowArtivion’s improving revenue base has not yet translated into consistently positive bottom-line earnings or free cash flow. Continued volatility can constrain internally funded investment, increase dependence on financing, and make the durability of earnings less predictable over the next several quarters.
Elevated Acquisition LeverageThe acquisition increased financial leverage and reduces flexibility while Artivion funds integration and commercial expansion. A 3.1x net leverage ratio means more operating cash may be required for debt service, leaving less capacity to absorb execution setbacks or sustain investment.
Margin And Operating-cost PressureHigher operating expenses and acquisition-related amortization are diluting the benefit of revenue growth, while the lower EBITDA margin signals weaker near-term operating leverage. Sustained cost growth would limit earnings conversion unless commercialization eventually outpaces integration and development spending.
AORT FAQ
What was Artivion’s price range in the past 12 months?
Artivion lowest stock price was $19.16 and its highest was $48.25 in the past 12 months.
What is Artivion’s market cap?
Artivion’s market cap is $1.13B.
When is Artivion’s upcoming earnings report date?
Artivion’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Artivion’s earnings last quarter?
Artivion released its earnings results on Aug 06, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of $0.002 by -$0.282.
Is Artivion overvalued?
According to Wall Street analysts Artivion’s price is currently Undervalued.
Does Artivion pay dividends?
Artivion pays a Quarterly dividend of $0.03 which represents an annual dividend yield of 1.15%. See more information on Artivion dividends here
What is Artivion’s EPS estimate?
Artivion’s EPS estimate is -0.06.
How many shares outstanding does Artivion have?
Artivion has 48,756,220 shares outstanding.
What happened to Artivion’s price movement after its last earnings report?
Artivion reported an EPS of -$0.28 in its last earnings report, missing expectations of $0.002. Following the earnings report the stock price went up 2.07%.
Which hedge fund is a major shareholder of Artivion?
Currently, no hedge funds are holding shares in AORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.31 (52.82% Upside)
$40.31 (52.82% Upside)
Blogger Sentiment
Bullish
AORT Sentiment 88%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 209.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.85%
12-Months-Change
Fundamentals
Return on Equity
-0.71%
Trailing 12-Months
Asset Growth
27.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Artivion
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
AORT Company Deck
AORT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive strategic and commercial story with multiple high‑impact milestones (AMDS PMA approval, Endospan/NEXUS acquisition, accelerating stent graft and On‑X growth) and reiterated full‑year guidance. These positives were offset by near‑term financial and operational headwinds: margin pressure, higher operating costs and amortization from the acquisition, negative free cash flow in the quarter driven by acquisition‑related cash outflows, and elevated leverage. Management emphasized that several lowlights are investment‑ or timing‑related and positioned as temporary as the business scales and NEXUS/AMDS commercialization progresses.View all AORT earnings summariesAORT Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$40.31
▲(52.82% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Edwards Lifesciences
―
Haemonetics
―
Medtronic
―
LivaNova
―
Anteris Technologies Global Corp.
―
Ownership Overview
5.07% Insiders
33.31% Mutual Funds
0.06% Other Institutional Investors
38.94% Public Companies and
Individual Investors









